about
Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infectionAbbott RealTime HBV assay is more sensitive in detection of low viral load and little impacted by drug resistant mutation in chronic hepatitis B patients under nucleot(s)ide analogues therapyThe serological and molecular epidemiology of GB virus C/hepatitis G virus infection in a hepatitis C and B endemic area.Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan.Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patientsLong-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.Hepatitis B virus genotyping by enzyme-linked immunosorbent assay in Taiwan.Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients.Risk interaction of obesity, insulin resistance and hormone-sensitive lipase promoter polymorphisms (LIPE-60 C > G) in the development of fatty liverPegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patientsCT evaluation of gastrointestinal tract perforation.Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients.Amiodarone as an autophagy promoter reduces liver injury and enhances liver regeneration and survival in mice after partial hepatectomyThe Paradoxical Effects of Different Hepatitis C Viral Loads on Host DNA Damage and Repair AbilitiesGlucose abnormalities in hepatitis C virus infection.Outcome assessment in acute pancreatitis patients.A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan.Hepatitis C virus infection among children in aboriginal areas in Taiwan.Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study.Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment.Clinical performance of a new hepatitis B surface antigen quantitative assay with automatic dilution.Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study.The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies.Viral hepatitis infections in southern Taiwan: a multicenter community-based study.Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study.Possible determinants of rapid virological response suggesting shorter courses of combination therapy for hepatitis C virus genotype 2.Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.Performance characteristics of a real-time RT-PCR assay for quantification of hepatitis C virus RNA in patients with genotype 1 and 2 infections.Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure.Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.Association between transforming growth factor-beta 1 polymorphism and virologic characteristics of chronic hepatitis C.A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors.A crossing in therapy for hepatitis C virus genotype 2 or 3: increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration.Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns.Insulin resistance, viral load and response to peginterferon and ribavirin in patients with chronic hepatitis C virus infection.HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link?Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.
P50
Q28537754-DF404D70-6D66-4A75-A389-1F39B96BE5E7Q28540452-09BBF385-70E2-43E7-BEE3-9895DCAC8259Q32179572-151EB8E1-3252-4D3C-80FC-B303E0EEE877Q33387627-A3CE816F-8C0B-4201-AFB7-57B64DFEA700Q33637279-61ED09D9-AD7C-422E-8C14-B1D88B87B7D4Q33637279-DDCAFDF0-AC2D-414D-864F-C8D7A8F0572AQ33939443-594E5062-B574-4C3E-B575-8B83DE651A3AQ34130417-FF15D7F6-6D26-413A-9B15-715613A53DF3Q34532854-69FFAA10-318D-4E58-83FD-9DAE456B87BEQ34634369-D2A6C6B3-98EC-4BEE-8A19-27CB80C3EB59Q34728811-C66285D0-9D06-4E15-8545-E17378A6817BQ35250340-536A95B7-7A3C-425D-B26D-B07466CE8E20Q35813637-4D9BEDEA-7AEA-4924-9427-C75233FF3E8AQ35911967-0A76CBCC-EB4F-4FFA-B0B5-D46F7D8BAEACQ36127895-678D728E-6FD3-4851-8DAE-57F54D80C050Q36227093-53367242-CA15-4BF9-BD68-992D9D4AFB92Q36239327-D8C0C98B-E1B2-48A0-832F-08AD87D2E2E5Q38076564-7CDFFA5F-427E-4E17-B93D-AB1B9079A3A1Q38135642-1789791F-4AB9-43C1-BCED-AAC6C83660E1Q39020570-2CF59AE7-1C89-4851-B0FB-485753CD7CCDQ39854829-EBB320CC-59AB-4EED-B3FA-C496DCC835DBQ40474459-BAE02A92-C0D0-48A7-B650-5787E68104C5Q40509070-A233BBFD-1058-438A-9771-236A12F4C781Q41534231-2B15E36D-9B4D-4F25-AA84-93F38E8DEB19Q42288395-B0E7F2E7-060A-4564-AD20-2658AE48C7E7Q42424919-EA3981E9-0D23-404B-BC5E-42B7B125ECD1Q42908922-4B19D849-B847-431D-8FAD-4EEBB58D2792Q42978491-B85AA60B-FD9C-4930-B6A2-2DCFAC2A5470Q42978688-AA14C14D-6373-4880-AABC-1A9883ED6F79Q42978706-2D9FB670-0A19-431B-ACA5-B98C96373169Q42979735-7342AAFB-CA57-4C69-83A4-7576081CEEEDQ42980368-E463864F-1C38-4F42-A29D-9BD149C11A89Q42981176-4EF50260-B569-45D2-A056-FBA78E798887Q42982454-5F3354BD-7F4B-4ACA-BAEC-0336EBD164A1Q42985657-2B1104AD-029D-478A-BF56-2D515CD256FFQ42986544-243CCE4C-A079-4D47-A263-890F455D4C7BQ42988105-390EADEB-905B-4390-A98D-6BC4E09CCD75Q42995237-00357290-5EC8-4599-8C50-43E4EE9AD652Q42997128-14DBA8B7-DAFF-4AF0-B4FF-5B78F53CDBD9Q43030689-2AAD837A-1F6F-44FB-8433-4964C369B433
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jee-Fu Huang
@ast
Jee-Fu Huang
@en
Jee-Fu Huang
@es
Jee-Fu Huang
@nl
Jee-Fu Huang
@sl
type
label
Jee-Fu Huang
@ast
Jee-Fu Huang
@en
Jee-Fu Huang
@es
Jee-Fu Huang
@nl
Jee-Fu Huang
@sl
prefLabel
Jee-Fu Huang
@ast
Jee-Fu Huang
@en
Jee-Fu Huang
@es
Jee-Fu Huang
@nl
Jee-Fu Huang
@sl
P106
P1153
57154862200
P31
P496
0000-0002-2752-7051